You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

CLINICAL TRIALS PROFILE FOR DEXAMETHASONE INTENSOL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Dexamethasone Intensol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00075725 ↗ Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 2003-12-29 This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
NCT00075725 ↗ Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed Children's Oncology Group Phase 3 2003-12-29 This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
NCT00098475 ↗ Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma Active, not recruiting National Cancer Institute (NCI) Phase 3 2004-10-26 This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide and thalidomide may also stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide, thalidomide, and dexamethasone together may kill more cancer cells.
NCT00103285 ↗ Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 2005-04-11 This randomized phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
NCT00103285 ↗ Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed Children's Oncology Group Phase 3 2005-04-11 This randomized phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dexamethasone Intensol

Condition Name

Condition Name for Dexamethasone Intensol
Intervention Trials
Recurrent Plasma Cell Myeloma 17
Acute Lymphoblastic Leukemia 15
Refractory Plasma Cell Myeloma 15
Untreated Adult Acute Lymphoblastic Leukemia 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dexamethasone Intensol
Intervention Trials
Neoplasms, Plasma Cell 33
Multiple Myeloma 33
Leukemia 33
Precursor Cell Lymphoblastic Leukemia-Lymphoma 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dexamethasone Intensol

Trials by Country

Trials by Country for Dexamethasone Intensol
Location Trials
Canada 104
Australia 57
New Zealand 24
Puerto Rico 12
Switzerland 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dexamethasone Intensol
Location Trials
Texas 42
California 39
Minnesota 37
Georgia 31
Ohio 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dexamethasone Intensol

Clinical Trial Phase

Clinical Trial Phase for Dexamethasone Intensol
Clinical Trial Phase Trials
Phase 3 18
Phase 2/Phase 3 3
Phase 2 37
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dexamethasone Intensol
Clinical Trial Phase Trials
Recruiting 42
Active, not recruiting 17
Not yet recruiting 15
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dexamethasone Intensol

Sponsor Name

Sponsor Name for Dexamethasone Intensol
Sponsor Trials
National Cancer Institute (NCI) 71
M.D. Anderson Cancer Center 17
Mayo Clinic 10
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dexamethasone Intensol
Sponsor Trials
Other 72
NIH 71
Industry 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Dexamethasone Intensol: Clinical Trials, Market Analysis, and Projections

Introduction to Dexamethasone Intensol

Dexamethasone Intensol is a concentrated oral solution of the synthetic corticosteroid dexamethasone. It is widely used for its potent anti-inflammatory and immunosuppressant properties, making it a versatile treatment for various medical conditions.

Clinical Trials and Uses

Multiple Myeloma Treatment

Dexamethasone is often used in combination therapies for treating multiple myeloma. A phase II trial (NCT03763162) investigates the efficacy of dexamethasone combined with daratumumab, bortezomib, and ixazomib in patients with relapsed or refractory multiple myeloma. This combination aims to enhance the body's immune response against cancer cells and inhibit tumor growth[4].

Pediatric Emergency Care

In pediatric care, dexamethasone has been studied for its effectiveness in acute moderate-to-severe bronchiolitis. A multicenter randomized controlled trial assesses the use of oral dexamethasone in reducing the need for hospital admission and improving respiratory scores. The study highlights the safety and efficacy of dexamethasone in this context, with a low rate of side effects[5].

COVID-19 Treatment

During the COVID-19 pandemic, dexamethasone gained significant attention for its effectiveness in treating critically ill patients. The University of Oxford's RECOVERY trial and subsequent recommendations by the World Health Organization (WHO) and the FDA have solidified its role in managing severe and critical COVID-19 cases[3].

Market Analysis

Global Market Size and Growth

The global dexamethasone market is projected to experience robust growth. According to Data Bridge Market Research, the market is expected to reach USD 4,634.01 million by 2028, growing at a CAGR of 6.65% from 2021 to 2028. This growth is driven by the increasing prevalence of various diseases, including allergic disorders, skin conditions, and COVID-19[2].

Market Segmentation

The dexamethasone market is segmented based on formulation type, patient type, application, and end users. The formulation types include liquid, tablet, solution for injection, and others. The patient types are categorized into adult, pediatric, and geriatric. Applications include anti-inflammatory and immunosuppressant effects, respiratory distress syndrome, COVID-19, and others. End users comprise hospitals, clinics, pharmacy & drug stores, and online pharmacies[2].

Geographical Distribution

North America leads the dexamethasone market due to the high prevalence of diseases and the rapid increase in COVID-19 cases. The Asia-Pacific region is expected to grow significantly, driven by the rising prevalence of viral disease outbreaks and the strong presence of major manufacturers in this region. The U.K. also holds a significant market share, particularly after the government stockpiled dexamethasone during the COVID-19 pandemic[2][3].

Key Drivers of Market Growth

Increasing Prevalence of Diseases

The rising incidence of chronic obstructive lung diseases, arthritis, and other inflammatory conditions is a major driver of the dexamethasone market. The COVID-19 pandemic has further accelerated the demand for dexamethasone due to its efficacy in treating critically ill patients[2][3].

Government Support and Regulatory Approvals

Government initiatives and regulatory approvals have played a crucial role in boosting the market. The FDA's approval for the use of dexamethasone in treating COVID-19 patients and the WHO's recommendations have significantly increased its adoption[3].

Expansion of Pharmaceutical Sector

The growth of the pharmaceutical sector, including investments in research and development, has contributed to the increasing availability and accessibility of dexamethasone. This expansion is expected to continue, offering lucrative opportunities for manufacturers[2].

Key Restraints

Side Effects and Development of Vaccines

Despite its benefits, dexamethasone is associated with various side effects, which can impede market growth. Additionally, the development of vaccines for diseases like COVID-19 may reduce the demand for dexamethasone in the long term[2][3].

Market Projections

Future Outlook

The global dexamethasone market is set to witness strong growth over the next decade. Fact.MR predicts that the market will total USD 46.9 billion by 2031, driven by the increasing prevalence of diseases and the continued use of dexamethasone in treating COVID-19 and other conditions[3].

Dominant Segments

The injectable segment is expected to remain dominant due to its quick action and preference in hospital emergency wards. The COVID-19 segment is anticipated to continue its dominance in the application segment of the dexamethasone market[3].

Competitive Landscape

Key Players and Strategies

The competitive landscape of the dexamethasone market includes various pharmaceutical companies that are adopting strategies such as increasing manufacturing, expanding distribution channels, and investing in research and development to gain a competitive edge. Government support and collaborations with healthcare providers are also crucial in this competitive environment[2][3].

Key Takeaways

  • Market Growth: The global dexamethasone market is expected to grow significantly, driven by the increasing prevalence of diseases and the impact of the COVID-19 pandemic.
  • Dominant Segments: Injectable formulations and COVID-19 treatment segments are expected to lead the market.
  • Geographical Distribution: North America and the Asia-Pacific region are key markets, with the U.K. also holding a significant share.
  • Key Drivers: Increasing disease prevalence, government support, and pharmaceutical sector expansion are major drivers.
  • Key Restraints: Side effects and the development of vaccines are potential restraints.

FAQs

What is Dexamethasone Intensol used for?

Dexamethasone Intensol is used for its anti-inflammatory and immunosuppressant properties to treat various conditions, including allergic disorders, skin diseases, arthritis, and COVID-19.

How has the COVID-19 pandemic affected the dexamethasone market?

The COVID-19 pandemic has significantly increased the demand for dexamethasone due to its efficacy in treating critically ill patients, leading to a surge in sales and market growth.

What are the dominant segments in the dexamethasone market?

The injectable segment and the COVID-19 treatment segment are expected to remain dominant in the dexamethasone market.

What are the key drivers of the dexamethasone market?

Key drivers include the increasing prevalence of diseases, government support, and the expansion of the pharmaceutical sector.

What are the potential restraints on the dexamethasone market?

Potential restraints include the side effects associated with dexamethasone and the development of vaccines for diseases like COVID-19.

Sources

  1. Boehringer Ingelheim - Dexamethasone Tablets Solution and Intensol.pdf
  2. Data Bridge Market Research - Global Dexamethasone Market – Industry Trends and Forecast to 2028
  3. Fact.MR - Dexamethasone Injectables to Remain Top Choice for Addressing Rising Cases of Inflammatory Conditions
  4. My Cancer Genome - Clinical Trial: NCT03763162 - Multiple Myeloma
  5. PECARN - Pediatric Emergency Care Applied Research Network - Protocol Version 4, 9/20/05

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.